Shruti Gaggar

Shruti Gaggar

Auto-generated profile, based on publicly available information

Shruti Gaggar

Center for Surgical Science, Zealand University Hospital, Køge, 4600, Denmark

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 May 2022 in Oncogenesis
Verified
Journal Article
Open access
PDF file
HRHans Henrik Raskov
Hans Henrik Raskov
Adile OrhanAdile Orhan
Adile Orhan
SGShruti Gaggar
Shruti Gaggar
IGIsmail Gögenur
Ismail Gögenur
Neutrophils are central mediators of innate and adaptive immunity and first responders to tissue damage. Although vital to our health, their activation, function, and resolution are critical to preventing chronic inflammation that may contribute to carcinogenesis. Cancers are associated with the expansion of the neutrophil compartment with an escalation in the number of polymorphonuclear myeloid-derived suppressor cells (PMN-MDSC) in the peripheral circulation and tumor microenvironment. Although phenotypically similar to classically activated neutrophils, PMN-MDSC is pathologically activated and immunosuppressive in nature. They dynamically interact with other cell populations and tissue components and convey resistance to anticancer therapies while accelerating disease progression and metastatic spread. Cancer-associated neutrophilia and tumor infiltration of neutrophils are significant markers of poor outcomes in many cancers. Recently, there has been significant progress in the identification of molecular markers of PMN-MDSC providing insights into the central role of PMN-MDSC in the local tumor microenvironment as well as the systemic immune response in cancer. Further advances in sequencing and proteomics techniques will improve our understanding of their diverse functionalities and the complex molecular mechanisms at play. Targeting PMN-MDSC is currently one of the major focus areas in cancer research and several signaling pathways representing possible treatment targets have been identified. Positive results from preclinical studies clearly justify the current investigation in drug development and thus novel therapeutic strategies are being evaluated in clinical trials. In this review, we discuss the involvement of PMN-MDSC in cancer initiation and progression and their potential as therapeutic targets and clinical biomarkers in different cancers.

1 November 2021 in Cancer Letters
Verified
Journal Article
Closed access
HRHans Henrik Raskov
Hans Henrik Raskov
Adile OrhanAdile Orhan
Adile Orhan
ASAli salanti
Ali salanti
SGShruti Gaggar
Shruti Gaggar
Ismail GögenurIsmail Gögenur
Ismail Gögenur

25 November 2022 in European Journal of Cancer
Verified
Journal Article
Open access
HRHans Henrik Raskov
Hans Henrik Raskov
SGShruti Gaggar
Shruti Gaggar
ATAsma Tajik
Asma Tajik
Adile OrhanAdile Orhan
Adile Orhan
IGIsmail Gögenur
Ismail Gögenur
Cell metabolism is characterised by the highly coordinated conversion of nutrients into energy and biomass. In solid cancers, hypoxia, nutrient deficiencies, and tumour vasculature are incompatible with accelerated anabolic growth and require a rewiring of cancer cell metabolism. Driver gene mutations direct malignant cells away from oxidation to maximise energy production and biosynthesis while tumour-secreted factors degrade peripheral tissues to fuel disease progression and initiate metastasis. As it is vital to understand cancer cell metabolism and survival mechanisms, this review discusses the metabolic switch and current drug targets and clinical trials. In the future, metabolic markers may be included when phenotyping individual tumours to improve the therapeutic opportunities for personalised therapy.